Photo taken from Elisa Agostinetto/LinkedIn
Apr 3, 2024, 15:19
Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter:
“Out in JAMA Oncology a pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC.
pCR was associated with EFS in HER2-E and basal, but not luminal subtypes.
Benefit of dual HER2 blockade (T+L) was restricted to HER2-E tumors.”
View the article attached to the post.
Source: Elisa Agostinetto/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56